Thyrocare Technologies Ltd logo

Thyrocare Technologies Ltd

THYROCARE NSE

Key Fundamentals

MicrocapHealthcare Service ProviderHealthcare Services
Market Cap
₹9,701 Cr
Volatility
Moderate
P/E Ratio
54.98
EBITDA
₹279 Cr
Return on Equity
27.79%
Debt to Equity
0.09
Book Value
₹32.21
EPS
₹14.66
52W High
₹662
52W Low
₹342.55

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Thyrocare Technologies Ltd insights

48 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 131%

Weaknesses

3
  • Stock is trading at 16.8 times its book value
  • Promoters have pledged 100% of their holding.
  • Promoter holding has decreased over last 3 years: -10.2%

Growth Rate

Revenue Growth
20.48% ↗
Net Income Growth
79.41% ↗
Cash Flow Change
11.45% ↗
ROE
67.51% ↗
ROCE
30.10% ↗
EBITDA Margin (Avg.)
12.87% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 42d ago
AI opinion · based on fundamentals
Risk high

Thyrocare Technologies trades at a market cap of ₹8,726 Cr with a PE of 54.2x and a price-to-book of 17.2x. The company is nearly debt-free with a last-year ROE of 28%, but faces significant governance concerns with 100% promoter pledge and declining promoter holding over 3 years by 10.2%.

Bull Case 8
  • Company is almost debt-free, providing financial flexibility and minimal interest burden
  • TTM profit growth of 85% signals a sharp recovery in earnings power
  • Last year ROE of 28% is well above the 10-year average of 21%, indicating improving capital efficiency
  • Compounded sales CAGR of 13% over 10 years reflects consistent top-line expansion in the diagnostics space
  • Dividend yield of 2.52% with a payout ratio of 131% demonstrates strong cash return to shareholders
  • 3-year compounded profit CAGR of 36% indicates accelerating earnings momentum beyond the long-term 12% trend
  • 1-year stock CAGR of 63% reflects market re-rating of the business on improved fundamentals
  • 5-year ROE consistency at 20% shows durable return generation through business cycles
Bear Case 8
  • Promoters have pledged 100% of their holding, creating severe governance and forced-selling risk
  • PE of 54.2x is expensive relative to the 10-year profit CAGR of just 12%, implying stretched valuations
  • Promoter holding has decreased by 10.2% over the last 3 years, signaling potential lack of insider confidence
  • Price-to-book of 17.2x (or 15.1x book value) makes the stock vulnerable to de-rating if growth slows
  • 5-year compounded profit CAGR of only 8% suggests the recent 85% TTM surge may not be sustainable long-term
  • 5-year stock CAGR of just 5% versus 10-year CAGR of 12% indicates prolonged underperformance in the medium term
  • Dividend payout ratio of 131% exceeds net profits, which may not be sustainable without retained earnings growth
  • 5-year sales CAGR of 11% is modest for a company trading at 54x earnings, creating a growth-valuation mismatch

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 42d ago
Positives 1
  • Strong FY26 revenue and profit Jun 30

    Thyrocare reported consolidated revenue of ₹829.04 crore and net profit of ₹162.85 crore for FY26. Shareholders approved a final dividend of ₹7 per share, signaling confidence in cash flows.

Neutral 1
  • New statutory auditor appointed Jun 30

    Thyrocare appointed M/s. Price Waterhouse Chartered Accountants LLP as statutory auditor for a five-year term starting June 30, 2026. This is a routine governance action with no operational impact.

TL;DR: Thyrocare closed FY26 with solid revenue and profitability, complemented by a ₹7 per share dividend. No material headwinds emerged in recent news. The appointment of PwC as auditor reflects standard governance hygiene. With steady financials and no visible risks in the near term, the outlook appears stable to mildly positive.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
135
148
135
154
157
177
166
187
193
217
196
224
240
Expenses
100
110
103
121
115
129
124
130
135
145
138
149
163
Operating Profit
35
38
32
34
42
48
42
57
58
71
58
75
77
OPM %
26%
25%
23%
22%
27%
27%
25%
30%
30%
33%
30%
34%
32%
Other Income
1
3
3
3
4
3
4
5
5
3
-1
5
5
Interest
1
1
1
1
1
1
1
1
1
1
0
2
1
Depreciation
10
11
13
13
11
13
17
14
11
12
22
14
12
PBT
25
28
20
23
34
37
28
47
50
63
35
64
68
Tax %
31%
28%
26%
25%
29%
28%
32%
54%
24%
24%
21%
24%
25%
Net Profit
17
20
15
17
24
26
19
22
38
48
28
49
51
EPS in Rs
1.09
1.28
0.97
1.12
1.52
1.68
1.2
1.36
2.45
3.02
1.82
2.96
3.28
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
183
241
304
356
403
434
495
589
527
572
687
829
876
Expenses
110
147
189
212
249
261
323
353
403
432
498
566
594
Operating Profit
73
94
115
145
154
174
171
236
123
140
190
263
282
OPM %
40%
39%
38%
41%
38%
40%
35%
40%
23%
24%
28%
32%
32%
Other Income
8
7
-15
21
11
1
12
29
9
9
15
12
12
Interest
0
1
0
0
1
2
1
3
5
6
4
4
3
Depreciation
13
18
18
20
26
32
30
34
39
47
55
59
60
PBT
68
82
82
145
138
140
152
228
89
96
145
213
231
Tax %
35%
37%
48%
36%
38%
37%
26%
23%
27%
28%
38%
24%
—
Net Profit
44
52
43
93
85
88
113
176
64
69
91
163
176
EPS in Rs
2.98
3.21
2.66
5.79
5.38
5.58
7.13
11.1
4.06
4.45
5.76
10.24
11.08
Div. Payout %
171%
104%
125%
58%
124%
30%
117%
45%
148%
135%
122%
137%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
51
54
54
54
53
53
53
53
53
53
53
159
Reserves
226
312
354
390
382
314
374
474
481
474
494
426
Borrowings
0
0
0
0
2
12
8
21
23
42
25
51
Other Liabilities
53
44
30
36
37
90
106
60
74
75
121
111
Total Liabilities
329
410
438
479
475
469
541
607
632
644
693
747
Fixed Assets
196
259
259
299
294
269
253
285
294
306
297
317
CWIP
6
1
17
0
1
5
8
3
2
3
14
3
Investments
86
93
104
120
95
90
126
146
144
162
162
177
Other Assets
42
56
58
60
84
105
154
173
192
173
220
250
Total Assets
329
410
438
479
475
469
541
607
632
644
693
747
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
34
68
90
107
100
168
115
113
129
168
191
213
Investing
-18
-18
-42
-43
-12
1
-49
-24
-39
-91
-53
-23
Financing
-23
-45
-49
-64
-94
-165
-62
-89
-86
-85
-130
-170
Net Cash Flow
-6
5
0
0
-5
4
4
0
4
-8
8
21
Free Cash Flow
25
53
53
63
61
158
93
99
88
107
146
198
CFO/OP
79
106
113
108
104
122
92
72
128
141
123
104
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
10
11
8
10
11
14
33
58
59
28
39
33
Inventory Days
48
56
65
66
60
64
52
53
62
104
89
81
Days Payable
5
10
6
25
25
68
56
36
54
88
146
109
Cash Conversion Cycle
53
57
67
50
46
10
29
75
67
44
-18
4
Working Capital Days
28
2
19
10
28
-8
19
41
31
7
13
19
ROCE %
—
24%
28%
33%
30%
35%
36%
42%
17%
18%
25%
35%

Shareholding Pattern

As of Jun 2026
Promoters 60.92%
DIIs 20.92%
Public 10.35%
FIIs 5.44%
Others 2.36%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
66.14%
66.14%
71.22%
71.18%
71.18%
71.18%
71.14%
71.14%
71.14%
71.14%
71.14%
71.11%
71.11%
71.11%
71.11%
71.06%
71.06%
71.06%
71.06%
60.93%
60.92%
60.92%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
3.46%
0.00%
2.90%
2.49%
1.93%
2.77%
2.41%
3.23%
4.85%
4.95%
5.37%
5.44%
DIIs
7.14%
6.17%
6.07%
6.37%
6.52%
6.68%
8.66%
8.69%
8.45%
13.46%
13.33%
13.55%
14.88%
14.90%
14.80%
14.67%
14.97%
14.54%
13.47%
20.51%
20.99%
20.92%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
5.01%
6.32%
7.60%
7.44%
6.65%
6.71%
7.28%
8.07%
8.38%
9.42%
9.66%
9.15%
8.48%
8.66%
9.78%
9.16%
9.21%
8.94%
8.19%
10.88%
10.18%
10.35%
Others
21.71%
21.37%
15.11%
15.01%
15.66%
15.43%
12.91%
12.10%
12.03%
5.97%
2.42%
6.19%
2.63%
2.84%
2.38%
2.33%
2.36%
2.23%
2.43%
2.73%
2.53%
2.36%
No. of Shareholders
0
44,722
53,140
62,936
65,769
66,315
66,431
71,412
74,386
76,292
72,000
68,844
64,823
61,636
59,377
56,666
57,403
54,566
54,142
77,969
73,377
73,064

Documents

Frequently Asked Questions about Thyrocare Technologies Ltd

What does Thyrocare Technologies Ltd do?
Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.
Where is Thyrocare Technologies Ltd (THYROCARE) listed?
Thyrocare Technologies Ltd is listed on the Indian stock exchanges. It is listed on NSE: THYROCARE and BSE: 539871. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Thyrocare Technologies Ltd belong to?
Thyrocare Technologies Ltd operates in the Healthcare sector within the Healthcare Services industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd has a market capitalisation of approximately ₹9701.13 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Thyrocare Technologies Ltd?
The Price-to-Earnings (PE) ratio of Thyrocare Technologies Ltd is 54.98. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Thyrocare Technologies Ltd?
Over the past 52 weeks, Thyrocare Technologies Ltd has traded between a low of ₹342.55 and a high of ₹662. This range helps investors understand the stock's price volatility and recent trading levels.
Does Thyrocare Technologies Ltd pay dividends?
Yes, Thyrocare Technologies Ltd has a dividend yield of 2.26%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Thyrocare Technologies Ltd?
Thyrocare Technologies Ltd has a Return on Equity (ROE) of 27.79%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Thyrocare Technologies Ltd on Tapetide?
On Tapetide, you can view Thyrocare Technologies Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.

Website thyrocare.com
CEO Mr. Rahul Franklin Guha
Employees 1,822
Listed 2016-05-09
Face Value ₹ 10
Issued Size 15,91,61,691

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List